Abstract 491P
Background
Furmonertinib (AST2818) is a novel, promising oral third-generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR sensitive mutations and T790M mutation, which has demonstrated efficacy in NSCLC in previous clinical trials. However, the efficacy and safety of furmonertinib as adjuvant therapy in patients ≥ 65 years old remain unclear.
Methods
Patients who underwent radical lung cancer surgery with EGFR mutations from two independent medical centers were enrolled and received furmonertinib 80mg daily. The adjuvant therapy time (6-36months) depended on patients’pathologic stage and physical conditions. The disease-free survival (DFS), safety and tolerability were evaluated.
Results
This study retrospectively analyzed 101 patients who were pathologically confirmed adenocarcinoma, EGFR mutation-positive (exon 19 deletion/L858R), stage IA2-IIIA NSCLC (60 females, 41 males, ranging in age from 43 to 86 years, with a median age of 65). Among them, 55 cases were ≥ 65 years old (median age 69 years, including 21 ≥ 70 years old), and 46 cases were<65 years old (median age 56.5 years old). All patients were followed at least 10 months, and 68 (67.3%) of them have been followed up for over 2 years, median follow-up time was 22 months. At data cutoff, all patients were alive, only 3 of them had metastasis (CNS, chest wall, and pancreas, respectively). The 2-year DFS rates for patients ≥ 65 years old and<65 years old were 96% and 97%, respectively (p=0.98). During therapy, 39 (38.6%) patients had treatment-related adverse events (TRAEs) of any grade. The most common TRAEs were rash (19/101, 18.8%), mouth ulcer (9/101, 8.9%) ,diarrhea (9/101, 8.9%) and transaminase elevation (5/101, 5.0%). Only 3 (3.0%) patients had TRAEs of grade 3 or higher and 1(1.4%) of them discontinued therapy. There was no significant difference in the incidence of TRAEs of any grade in patients aged ≥ 65 years and < 65 years (30.9% and 47.8%, p=0.08, respectively).
Conclusions
This is the first real-world study to demonstrate that furmonertinib has good efficacy and a tolerable safety profile in elderly patients (≥ 65 years) with completely resected stage I-III NSCLC harboring EGFR mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract